FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ...

While retrieval-augmented generation is effective for simpler queries, advanced reasoning questions require deeper connections between information that exist across documents. They require a knowledge ...

Discover how to effortlessly create stunning, interactive charts with Syncfusion in .NET MAUI. Enhance your mobile and desktop applications with powerful data visualization features using this ...

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...

Cartesian is among the leaders in a push by drugmakers to develop cell therapies for autoimmune conditions. Like Kyverna Therapeutics, Cabaletta Bio and many others, the company aims to show that a ...

Moving an object from one location to another—picking and placing—is an ideal application for industrial robots due to the robots’ repeatability, throughput and favorable return on investment. It is ...

The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...